Phase II study of low-dose docetaxel/estramustine in elderly patients or patients aged 18-74 years with hormone-refractory prostate cancer

Clinical Genitourinary Cancer

Volumn 5, Issue 3, 2006, Pages 212-218

  Chittoor, Sreeni ^a,b   Berry, William ^a,c   Loesch, David ^a,d   Logie, Keith ^a,d   Fleagle, John ^a,e   Mull, Stephanie ^a   Boehm, Kristi A ^a   Zhan, Feng ^a   Asmar, Lina ^a  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b TEXAS ONCOLOGY   (United States)

^c Cancer Centers of North Carolina   (United States)

^d Central Indiana Cancer Centers   (United States)

^e ROCKY MOUNTAIN CANCER CENTERS   (United States)

Author keywords

Adults; High risk disease; Multicenter trials; Poor performance status

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; FLUTAMIDE; GOSERELIN; LEUPRORELIN; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; HEART ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; QUALITY OF LIFE; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 33846691931     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2006.n.039     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106-130.
2. Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 1999; 25(5 suppl 17):14-18.
3. Ringel I, Horwitz S. Studies with RP56976 (Taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst 1988; 83:288-291.
4. Yagoda A, Smith J Jr, Soloway M, et al. Phase II study of estramustine phosphate in advanced hormone refractory prostate cancer with increasing prostate specific antigen levels. J Urol 1991; 145:384A.
5. Kreis W, Budman D, Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 1997; 79:196-202.
6. Petrylak D, Macarthur R, O'Connor J, et al. Phase I trial of docetaxel with estramustine in androgen independent prostate cancer. J Clin Oncol 1999; 17:958-967.
7. Petrylak DP, Tangen CM, Houssain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-1520.
8. Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J Clin Oncol 2001; 19:2509-2516.
9. Kreis W, Budman D, Fetten J, et al. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 1999; 10:33-38.
10. Berry W, Dakhil S, Gregurich MA, et al. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 2001; 28(4 suppl 15):8-15.
11. Votron L, D'Hoore W, Swine C, et al. The opinion of general practitioners on the treatment of prostate and breast cancer in elderly people: results of a survey based on clinical models. Clin Oncol (R Coll Radiol) 2004; 16:474-478.
12. Maeda O, Kakimoto K, Ono Y, et al. Watchful waiting for elderly patients with localized prostate cancer. Hinyokika Kiyo 2005; 51:561-563.
13. Newschaffer CJ, Otani K, McDonald MK, et al. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst 2000; 92:613-621.
14. Konstantinos H. Prostate cancer in the elderly. Int Urol Nephrol 2005; 37:797-806.
15. Kanamaru H, Arai Y, Moroi S, et al. Long-term results of definitive treatment in elderly patients with localized prostate cancer. Int J Urol 1998; 5:546-549.
16. Kirk D. Prostate cancer in the elderly. Eur J Surg Oncol 1998; 24:379-383.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 95:205-216.
18. National Cancer Institute, Common Toxicity Criteria (version 2.0). Available at: http://ctep.cancer.gov/reporting/CTC-3test.html. Accessed October 7, 2005.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. JASA 1958; 53:457-481.
20. Freyer G, Geay JF, Touzet S, et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol 2005 [Epub ahead of print].
21. Goffin JR, Rajan R, Souhami L. Tolerance of radiotherapy and chemotherapy in elderly patients with bladder cancer. Am J Clin Oncol 2004; 27:172-177.
22. Ibrahim NK, Frye DK, Buzdar AU, et al. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med 1996; 156:882-888.
23. Terret C, Albrand G, Droz JP. Geriatric assessment in elderly patients with prostate cancer. Clin Prostate Cancer 2004; 2:236-240.
24. Beer TM, Berry W, Wersinger EM, et al. Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years. Clin Prostate Cancer 2003; 2:167-172.
25. Font A, Murias A, Arroyo FR, et al. Sequential mitoxamrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study. Ann Oncol 2005; 16:419-424.
26. Oh WK, Hagmann E, Manola J, et al. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005; 11:284-289.
27. Tiffany NM, Ryan CW, Garzotto M, et al. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study. J Urol 2005; 174:888-892.
28. Safarinejad MR. Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer. Urol Oncol 2005; 23:93-101.
29. Oudard S, Banu E, Beuzeboc P, et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005; 23:3343-3351.
30. Efstathiou E, Bozas G, Kostakopoulos A, et al. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment. Urology 2005; 65:126-130.
31. Fizazi K, Sikes CR, Kim J, et al. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res 2004; 24:2897-2903.
32. Oudard S, Legrier ME, Boye K, et al. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol 2003; 169:1729-1734.
33. Hussain M, Smith DC, El-Rayes BF, et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. Urology 2003; 61:774-780.
34. Sinibaldi VJ, Cardussi MA, Moore-Cooper S, et al. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 2002; 94:1457-1465.
35. Sitka Copur M, Ledakis P, Lynch J, et al. Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer. Semin Oncol 2001; 28(4 suppl 15):16-21.
36. Vaishampayan U, Fontana J, Du W, et al. An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer. Urology 2002; 60:1050-1054.
37. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512.
38. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-1520.